Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Vojtěch Tretera

3PUBLICATIONS

11CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Jun 27, 2025

Prognostic Biomarkers for Anti-PD-1 Monoclonal Antibodies in the First Line Treatment of Advanced Melanoma.

Marek Pásek, Emanuel Marques, Vojtěch Tretera

|Sep 11, 2024

Extracorporeal photophoresis in treatment of corticosteroid refractory colitis induced by combined immunotherapy for metastatic melanoma.

Marek Pásek, Jindřich Kopecký, Vojtěch Tretera

|Mar 16, 2024

The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.

Jindřich Kopecký, Marek Pásek, Radek Lakomý

Pageof 1

Frequent Collaborators

3 joint publications

Marek Pásek

3 joint publications

Monika Arenbergerová

2 joint publications

Jindřich Kopecký

2 joint publications

Petr Arenberger

1 joint publications

Radek Lakomý

1 joint publications

Bohuslav Melichar

1 joint publications

Ondřej Kubeček

1 joint publications

Radmila Lemstrová

1 joint publications

Emanuel Marques

1 joint publications

Jiří Šilar

Frequent Collaborators

3 joint publications

Marek Pásek

3 joint publications

Monika Arenbergerová

2 joint publications

Jindřich Kopecký

2 joint publications

Petr Arenberger

Top Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on : May 17, 2019

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1<sup>+</sup> Tim-3<sup>+</sup> CD8<sup>+</sup> T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1<sup>+</sup> Tim-3<sup>+</sup> CD8<sup>+</sup> T Cells

Published on : Feb 08, 2018

See more related videos

Top Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on : Feb 07, 2021

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on : May 17, 2019

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1<sup>+</sup> Tim-3<sup>+</sup> CD8<sup>+</sup> T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1<sup>+</sup> Tim-3<sup>+</sup> CD8<sup>+</sup> T Cells

Published on : Feb 08, 2018

See more related videos